tiprankstipranks
Advertisement
Advertisement

CH:1CG Stock Latest News

Citi says Novartis news increases likelihood Crispr prioritizes next-gen CTX321
The FlyCiti says Novartis news increases likelihood Crispr prioritizes next-gen CTX321
7h ago
NVS
CRSP
Crispr Therapeutics Maintained at Buy as Lp(a) Program Prospects Support Unchanged $88 Price Target
PremiumRatings
Crispr Therapeutics Maintained at Buy as Lp(a) Program Prospects Support Unchanged $88 Price Target
8h ago
CRSP
Crispr Therapeutics durability data ‘encouraging,’ says Morgan Stanley
PremiumThe Fly
Crispr Therapeutics durability data ‘encouraging,’ says Morgan Stanley
10d ago
CRSP
Crispr Therapeutics price target raised to $55 from $48 at Goldman Sachs
PremiumThe Fly
Crispr Therapeutics price target raised to $55 from $48 at Goldman Sachs
1M ago
CRSP
Crispr Therapeutics price target lowered to $82 from $83 at BofA
PremiumThe Fly
Crispr Therapeutics price target lowered to $82 from $83 at BofA
1M ago
CRSP
Crispr Therapeutics price target raised to $55 from $48 at Goldman Sachs
PremiumThe FlyCrispr Therapeutics price target raised to $55 from $48 at Goldman Sachs
1M ago
CRSP
CRISPR Therapeutics: Buy Rating Reiterated, $80 Price Target Maintained Ahead of Key HORIZON Catalyst
Premium
Ratings
CRISPR Therapeutics: Buy Rating Reiterated, $80 Price Target Maintained Ahead of Key HORIZON Catalyst
1M ago
CRSP
Analyst Maintains Buy on CRISPR Therapeutics as Casgevy Ramp and Diversified Pipeline Strengthen Long-Term Growth Outlook
Premium
Ratings
Analyst Maintains Buy on CRISPR Therapeutics as Casgevy Ramp and Diversified Pipeline Strengthen Long-Term Growth Outlook
1M ago
CRSP
Crispr Therapeutics: Strong Casgevy Uptake, Expanding Pipeline and Cash Runway Support Unchanged $82 Price Target and Buy Rating
PremiumRatings
Crispr Therapeutics: Strong Casgevy Uptake, Expanding Pipeline and Cash Runway Support Unchanged $82 Price Target and Buy Rating
1M ago
CRSP
Casgevy Momentum and Pipeline Catalysts Drive Yigal Nochomovitz to Maintain Buy Rating and Raise Price Target to $88
PremiumRatings
Casgevy Momentum and Pipeline Catalysts Drive Yigal Nochomovitz to Maintain Buy Rating and Raise Price Target to $88
1M ago
CRSP
Citi ups Crispr Therapeutics target on Casgvey momentum
PremiumThe Fly
Citi ups Crispr Therapeutics target on Casgvey momentum
1M ago
CRSP
Crispr Therapeutics price target raised to $88 from $82 at Citi
PremiumThe Fly
Crispr Therapeutics price target raised to $88 from $82 at Citi
1M ago
CRSP
Crispr Therapeutics reports Q2 EPS (94c), consensus ($1.18)
PremiumThe FlyCrispr Therapeutics reports Q2 EPS (94c), consensus ($1.18)
1M ago
CRSP
Crispr Therapeutics AG Slides Despite Bullish Wall Street
Premium
Weekend Updates
Crispr Therapeutics AG Slides Despite Bullish Wall Street
2M ago
CRSP
CRISPR Therapeutics: Buy Rating Reiterated as Pediatric CASGEVY Label Expands; $80 Price Target Maintained
Premium
Ratings
CRISPR Therapeutics: Buy Rating Reiterated as Pediatric CASGEVY Label Expands; $80 Price Target Maintained
2M ago
CRSP
Gil Blum Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target on Pipeline Upside and 2026 Data Catalysts
PremiumRatings
Gil Blum Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target on Pipeline Upside and 2026 Data Catalysts
3M ago
CRSP
Private Markets: Bezos’ Prometheus raises $12B as OpenAI files for IPO
PremiumThe Fly
Private Markets: Bezos’ Prometheus raises $12B as OpenAI files for IPO
3M ago
GS
TP
Crispr Therapeutics assumed at Equal Weight from Underweight at Morgan Stanley
PremiumThe Fly
Crispr Therapeutics assumed at Equal Weight from Underweight at Morgan Stanley
3M ago
CRSP
Shareholders Approve New Incentive Plan and Governance Measures
PremiumCompany Announcements
Shareholders Approve New Incentive Plan and Governance Measures
3M ago
8K
CRSP
FDA issues draft guidance to help accelerated cell, gene therapies for patients
PremiumThe FlyFDA issues draft guidance to help accelerated cell, gene therapies for patients
3M ago
AZN
BMY
Crispr Therapeutics price target raised to $56 from $50 at Bernstein
Premium
The Fly
Crispr Therapeutics price target raised to $56 from $50 at Bernstein
4M ago
CRSP
FDA Commissioner Marty Makary resigns
Premium
The Fly
FDA Commissioner Marty Makary resigns
4M ago
AZN
BMY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >